Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
- Author
- BYRD, John C1 2 ; LIN, Thomas S1 ; BROERING, Sarah1 ; SCHAAF, Larry J1 ; JOHNSON, Amy J1 ; LUCAS, David M1 ; HEEREMA, Nyla A5 ; LOZANSKI, Gerard5 ; YOUNG, Donn C6 ; SUAREZ, Jose-Ramon7 ; DIMITRIOS COLEVAS, A8 ; GREVER, Michael R1 ; DALTON, James T1 3 ; DI WU3 ; PHELPS, Mitch A3 ; FISCHER, Beth1 ; MORAN, Mollie1 ; BLUM, Kristie A1 ; ROVIN, Brad4 ; BROOKER-MCELDOWNEY, Michelle1
[1] Division of Hematology-Oncology, Department of Internal Medicine, The Ohio State University, Columbus, United States
[2] Department of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, United States
[3] Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, United States
[4] Division of Nephrology, Department of Medicine, The Ohio State University, Columbus, United States
[5] Department of Pathology, The Ohio State University, Columbus, United States
[6] Biostatistical Core, Comprehensive Cancer Center, The Ohio State University, Columbus, United States
[7] Sanofi-Aventis Pharmaceuticals, Bridgewater, NJ, United States
[8] Cancer Therapy and Evaluation Program, National Cancer Institute, Bethesda, MD, United States - Source
Blood. 2007, Vol 109, Num 2, pp 399-404, 6 p ; ref : 40 ref
- ISSN
- 0006-4971
- Scientific domain
- Medical oncology; Hematology
- Publisher
- The Americain Society of Hematology, Washington, DC
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Efficacité traitement Flavopiridol Génétique Hématologie Risque élevé Résistance traitement Inhibiteur kinases cycline-dépendantes Leucémie lymphoïde chronique Flavonoïde Hémopathie maligne Phénols Polyphénol Purine dérivé
- Keyword (en)
- Antineoplastic agent Treatment efficiency Flavopiridol Genetics Hematology High risk Treatment resistance Chronic lymphocytic leukemia Flavonoid Malignant hemopathy Phenols Polyphenol Purine derivatives
- Keyword (es)
- Anticanceroso Eficacia tratamiento Flavopiridol Genética Hematología Riesgo alto Resistencia tratamiento Leucemia linfoidea Flavonoide Hemopatía maligna Fenoles Polifenol Purina derivado
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B19 Hematologic and hematopoietic diseases / 002B19B Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
- Discipline
- Blood diseases
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 18439324
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1182/blood-2006-05-020735 
https://dx.doi.org/10.1182/blood-2006-05-020735
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2006-05-020735\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:178:\"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia\";s:9:\"\u0000*\u0000jtitle\";s:5:\"Blood\";s:9:\"\u0000*\u0000stitle\";s:5:\"Blood\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"399\";s:8:\"\u0000*\u0000epage\";s:3:\"404\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0006-4971\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"BYRD\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:13:\"LIN, Thomas S\";i:1;s:15:\"BROERING, Sarah\";i:2;s:15:\"SCHAAF, Larry J\";i:3;s:14:\"JOHNSON, Amy J\";i:4;s:14:\"LUCAS, David M\";i:5;s:15:\"HEEREMA, Nyla A\";i:6;s:16:\"LOZANSKI, Gerard\";i:7;s:13:\"YOUNG, Donn C\";i:8;s:18:\"SUAREZ, Jose-Ramon\";i:9;s:20:\"DIMITRIOS COLEVAS, A\";i:10;s:17:\"GREVER, Michael R\";i:11;s:15:\"DALTON, James T\";i:12;s:5:\"DI WU\";i:13;s:15:\"PHELPS, Mitch A\";i:14;s:13:\"FISCHER, Beth\";i:15;s:13:\"MORAN, Mollie\";i:16;s:15:\"BLUM, Kristie A\";i:17;s:11:\"ROVIN, Brad\";i:18;s:28:\"BROOKER-MCELDOWNEY, Michelle\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:178:\"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"The Americain Society of Hematology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2006-05-020735\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:178:\"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia\";s:9:\"\u0000*\u0000jtitle\";s:5:\"Blood\";s:9:\"\u0000*\u0000stitle\";s:5:\"Blood\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"399\";s:8:\"\u0000*\u0000epage\";s:3:\"404\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0006-4971\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"BYRD\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:13:\"LIN, Thomas S\";i:1;s:15:\"BROERING, Sarah\";i:2;s:15:\"SCHAAF, Larry J\";i:3;s:14:\"JOHNSON, Amy J\";i:4;s:14:\"LUCAS, David M\";i:5;s:15:\"HEEREMA, Nyla A\";i:6;s:16:\"LOZANSKI, Gerard\";i:7;s:13:\"YOUNG, Donn C\";i:8;s:18:\"SUAREZ, Jose-Ramon\";i:9;s:20:\"DIMITRIOS COLEVAS, A\";i:10;s:17:\"GREVER, Michael R\";i:11;s:15:\"DALTON, James T\";i:12;s:5:\"DI WU\";i:13;s:15:\"PHELPS, Mitch A\";i:14;s:13:\"FISCHER, Beth\";i:15;s:13:\"MORAN, Mollie\";i:16;s:15:\"BLUM, Kristie A\";i:17;s:11:\"ROVIN, Brad\";i:18;s:28:\"BROOKER-MCELDOWNEY, Michelle\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:178:\"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"The Americain Society of Hematology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2006-05-020735\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2006-05-020735\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:178:\"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia\";s:9:\"\u0000*\u0000jtitle\";s:5:\"Blood\";s:9:\"\u0000*\u0000stitle\";s:5:\"Blood\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"399\";s:8:\"\u0000*\u0000epage\";s:3:\"404\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0006-4971\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"BYRD\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:13:\"LIN, Thomas S\";i:1;s:15:\"BROERING, Sarah\";i:2;s:15:\"SCHAAF, Larry J\";i:3;s:14:\"JOHNSON, Amy J\";i:4;s:14:\"LUCAS, David M\";i:5;s:15:\"HEEREMA, Nyla A\";i:6;s:16:\"LOZANSKI, Gerard\";i:7;s:13:\"YOUNG, Donn C\";i:8;s:18:\"SUAREZ, Jose-Ramon\";i:9;s:20:\"DIMITRIOS COLEVAS, A\";i:10;s:17:\"GREVER, Michael R\";i:11;s:15:\"DALTON, James T\";i:12;s:5:\"DI WU\";i:13;s:15:\"PHELPS, Mitch A\";i:14;s:13:\"FISCHER, Beth\";i:15;s:13:\"MORAN, Mollie\";i:16;s:15:\"BLUM, Kristie A\";i:17;s:11:\"ROVIN, Brad\";i:18;s:28:\"BROOKER-MCELDOWNEY, Michelle\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:178:\"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"The Americain Society of Hematology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2006-05-020735\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:178:\"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia\";s:9:\"\u0000*\u0000jtitle\";s:5:\"Blood\";s:9:\"\u0000*\u0000stitle\";s:5:\"Blood\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"399\";s:8:\"\u0000*\u0000epage\";s:3:\"404\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0006-4971\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"BYRD\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:13:\"LIN, Thomas S\";i:1;s:15:\"BROERING, Sarah\";i:2;s:15:\"SCHAAF, Larry J\";i:3;s:14:\"JOHNSON, Amy J\";i:4;s:14:\"LUCAS, David M\";i:5;s:15:\"HEEREMA, Nyla A\";i:6;s:16:\"LOZANSKI, Gerard\";i:7;s:13:\"YOUNG, Donn C\";i:8;s:18:\"SUAREZ, Jose-Ramon\";i:9;s:20:\"DIMITRIOS COLEVAS, A\";i:10;s:17:\"GREVER, Michael R\";i:11;s:15:\"DALTON, James T\";i:12;s:5:\"DI WU\";i:13;s:15:\"PHELPS, Mitch A\";i:14;s:13:\"FISCHER, Beth\";i:15;s:13:\"MORAN, Mollie\";i:16;s:15:\"BLUM, Kristie A\";i:17;s:11:\"ROVIN, Brad\";i:18;s:28:\"BROOKER-MCELDOWNEY, Michelle\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:178:\"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"The Americain Society of Hematology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:28:\"10.1182\/blood-2006-05-020735\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:178:\"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia\";s:9:\"\u0000*\u0000jtitle\";s:5:\"Blood\";s:9:\"\u0000*\u0000stitle\";s:5:\"Blood\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"109\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"399\";s:8:\"\u0000*\u0000epage\";s:3:\"404\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0006-4971\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"BYRD\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John C\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:13:\"LIN, Thomas S\";i:1;s:15:\"BROERING, Sarah\";i:2;s:15:\"SCHAAF, Larry J\";i:3;s:14:\"JOHNSON, Amy J\";i:4;s:14:\"LUCAS, David M\";i:5;s:15:\"HEEREMA, Nyla A\";i:6;s:16:\"LOZANSKI, Gerard\";i:7;s:13:\"YOUNG, Donn C\";i:8;s:18:\"SUAREZ, Jose-Ramon\";i:9;s:20:\"DIMITRIOS COLEVAS, A\";i:10;s:17:\"GREVER, Michael R\";i:11;s:15:\"DALTON, James T\";i:12;s:5:\"DI WU\";i:13;s:15:\"PHELPS, Mitch A\";i:14;s:13:\"FISCHER, Beth\";i:15;s:13:\"MORAN, Mollie\";i:16;s:15:\"BLUM, Kristie A\";i:17;s:11:\"ROVIN, Brad\";i:18;s:28:\"BROOKER-MCELDOWNEY, Michelle\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:178:\"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia\";s:8:\"\u0000*\u0000place\";s:14:\"Washington, DC\";s:6:\"\u0000*\u0000pub\";s:35:\"The Americain Society of Hematology\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
